Ozempic, Mounjaro, Wegovy, or Zepbound? This ETF Holds Them All

Core Insights - Healthcare stocks have rebounded, outperforming other sectors in the S&P 500, largely driven by the demand for weight-loss drugs like GLP-1 agonists and semaglutide treatments [2][4] - The FDA's recent approval of pill forms of weight-loss drugs is expected to further catalyze market growth in 2026 [2][6] - The GLP-1 drug market is projected to grow at a compound annual growth rate (CAGR) of 18.54% from 2024 to 2030, increasing its market value from $13.84 billion to $48.84 billion [3][6] Industry Performance - The healthcare sector has shown the best performance among the 11 S&P 500 sectors in the last six months, primarily due to the popularity of injectable weight-loss treatments [2] - North America leads the GLP-1 agonists market, contributing nearly 76% of total revenue [4] Company Developments - Major companies like Novo Nordisk and Eli Lilly have benefited significantly from the weight-loss drug market, with their products Ozempic, Wegovy, Zepbound, and Mounjaro driving growth [4] - Pfizer has made a strategic move into the weight-loss sector by signing a $2.1 billion licensing agreement to develop an early-stage weight-loss pill [5] Investment Opportunities - The Roundhill GLP-1 & Weight Loss ETF offers investors exposure to a diversified portfolio of companies involved in the weight-loss drug market, having gained 52% over the past year [6]